Skip to content
OpenCapital
Get started

Krystal Biotech, Inc. KRYS Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value at other companies

Merck & Co. logo
Merck & Co.MRK
——

Other financials

Income statement

See full
Revenue$116.4M+31.9%
Operating income$53.7M+48.1%
Net income$55.9M+56.5%
EPS (diluted)$1.83+52.5%

Balance sheet

See full
Cash & equivalents$501.3M+62.4%
Total debt$9.1M-5.7%
Total equity$1.3B+29.7%
Total assets$1.4B+30.0%

Cash flow

See full
Operating cash flow$80.4M+160%
CapEx$7.1M+15.2%
Free cash flow$73.2M+196%

Valuation

See full
Market cap$10.26B+45.4%
Enterprise value$9.77B+44.2%
P/E45.6×-11.3×
P/S24.6×+3.4×

Profitability

See full
Operating margin42.8%+10.2pp
Net margin53.9%+16.7pp
FCF margin56.9%+16.5pp

Returns & leverage

See full
Return on equity19.9%+6.0pp
Debt / equity0×0.0×
Current ratio9.5×-0.2×

Where this comes from

Reported directly by Krystal Biotech, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1.

The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Krystal Biotech, Inc.'s share-based compensation arrangement by share-based payment award, options, exercisable, intrinsic value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Krystal Biotech, Inc.'s share-based compensation arrangement by share-based payment award, options, exercisable, intrinsic value?
Krystal Biotech, Inc. (KRYS) reported share-based compensation arrangement by share-based payment award, options, exercisable, intrinsic value of $222.47M in Q1 2026.
How has Krystal Biotech, Inc.'s share-based compensation arrangement by share-based payment award, options, exercisable, intrinsic value changed year-over-year?
Krystal Biotech, Inc.'s share-based compensation arrangement by share-based payment award, options, exercisable, intrinsic value increased by 71.1% year-over-year, from $130.02M to $222.47M.